195 related articles for article (PubMed ID: 10211757)
21. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
Cancer; 2002 Aug; 95(3):576-80. PubMed ID: 12209750
[TBL] [Abstract][Full Text] [Related]
22. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features.
Gill S; Herbert KE; Prince HM; Wolf MM; Wirth A; Ryan G; Carney DA; Ritchie DS; Davies JM; Seymour JF
Br J Haematol; 2009 Oct; 147(1):83-8. PubMed ID: 19694718
[TBL] [Abstract][Full Text] [Related]
23. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience.
Zinzani PL; Magagnoli M; Frezza G; Prologo G; Gherlinzoni F; Bendandi M; Albertini P; Babini L; D'Alessandro R; Tura S
Leuk Lymphoma; 1999 Feb; 32(5-6):571-6. PubMed ID: 10048430
[TBL] [Abstract][Full Text] [Related]
24. [Treatment results and the prognosis in patients with localization of non-Hodgkins-lymphoma in the central nervous system].
Paulus JA; Bos GM; Löwenberg B; Van Den Bent MJ
Ned Tijdschr Geneeskd; 1998 Oct; 142(40):2196-200. PubMed ID: 9864481
[TBL] [Abstract][Full Text] [Related]
25. Risk factors of central nervous system relapse in mantle cell lymphoma.
Conconi A; Franceschetti S; Lobetti-Bodoni C; Stathis A; Margiotta-Casaluci G; Ramponi A; Mazzucchelli L; Bertoni F; Ghielmini M; Gaidano G; Cavalli F; Zucca E
Leuk Lymphoma; 2013 Sep; 54(9):1908-14. PubMed ID: 23339449
[TBL] [Abstract][Full Text] [Related]
26. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989.
Miller DC; Hochberg FH; Harris NL; Gruber ML; Louis DN; Cohen H
Cancer; 1994 Aug; 74(4):1383-97. PubMed ID: 8055462
[TBL] [Abstract][Full Text] [Related]
27. Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers.
Jurczak W; Kroll-Balcerzak R; Giebel S; Machaczka M; Giza A; Ogórka T; Fornagiel S; Rybka J; Wróbel T; Kumiega B; Skotnicki AB; Komarnicki M
Med Oncol; 2015 Apr; 32(4):90. PubMed ID: 25716885
[TBL] [Abstract][Full Text] [Related]
28. Non Hodgkin's lymphoma involving the adrenal glands and the central nervous system (CNS): a particular evolution after chemotherapy.
Vélayoudom FL; Cardot-Bauters C; Decouvelaere AV; Vlaeminck V; Bauters F; Wémeau JL
Ann Endocrinol (Paris); 2005 Dec; 66(6):527-31. PubMed ID: 16357815
[TBL] [Abstract][Full Text] [Related]
29. Central nervous system lymphomas: a histologic and immunophenotypic analysis.
Muzaffar S; Siddiqui MS; Siddiqui I; Soomro IN; Pervez S; Kayani N; Hasan SH
J Pak Med Assoc; 2000 May; 50(5):141-4. PubMed ID: 11242711
[TBL] [Abstract][Full Text] [Related]
30. High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement.
Qualls D; Sullivan A; Li S; Brunner AM; Collier K; Hochberg E; Armand P; Batchelor TT; Chen YB; DeFilipp Z
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):884-888. PubMed ID: 28870642
[TBL] [Abstract][Full Text] [Related]
31. Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma.
Bashir RM; Bierman PJ; Vose JM; Weisenburger DD; Armitage JO
Am J Clin Oncol; 1991 Dec; 14(6):478-82. PubMed ID: 1720278
[TBL] [Abstract][Full Text] [Related]
32. Central nervous system involvement in T-cell lymphoma: A single center experience.
Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
[TBL] [Abstract][Full Text] [Related]
33. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis, prevention and treatment of central nervous system involvement in peripheral t-cell lymphomas.
Zing N; Fischer T; Federico M; Chiattone C; Ferreri AJM
Crit Rev Oncol Hematol; 2021 Nov; 167():103496. PubMed ID: 34653598
[TBL] [Abstract][Full Text] [Related]
35. Central Nervous System Lymphomas.
Grommes C
Continuum (Minneap Minn); 2020 Dec; 26(6):1476-1494. PubMed ID: 33273169
[TBL] [Abstract][Full Text] [Related]
36. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
37. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma.
Chua SL; Seymour JF; Streater J; Wolf MM; Januszewicz EH; Prince HM
Leuk Lymphoma; 2002 Sep; 43(9):1783-8. PubMed ID: 12685832
[TBL] [Abstract][Full Text] [Related]
38. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy.
Bokstein F; Lossos A; Lossos IS; Siegal T
Leuk Lymphoma; 2002 Mar; 43(3):587-93. PubMed ID: 12002763
[TBL] [Abstract][Full Text] [Related]
39. The role of SOX11 immunostaining in confirming the diagnosis of mantle cell lymphoma on fine-needle aspiration samples.
Zhang YH; Liu J; Dawlett M; Guo M; Sun X; Gong Y
Cancer Cytopathol; 2014 Dec; 122(12):892-7. PubMed ID: 25056830
[TBL] [Abstract][Full Text] [Related]
40. Non-Hodgkin's lymphoma and the CNS: prophylaxis and therapy in immunocompetent and HIV-positive individuals.
Mazhar D; Stebbing J; Bower M
Expert Rev Anticancer Ther; 2006 Mar; 6(3):335-41. PubMed ID: 16503851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
